Nordeen, S.K.; Su, L.-J.; Osborne, G.A.; Hayman, P.M.; Orlicky, D.J.; Wessells, V.M.; van Bokhoven, A.; Flaig, T.W.
Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. Life 2021, 11, 884.
https://doi.org/10.3390/life11090884
AMA Style
Nordeen SK, Su L-J, Osborne GA, Hayman PM, Orlicky DJ, Wessells VM, van Bokhoven A, Flaig TW.
Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. Life. 2021; 11(9):884.
https://doi.org/10.3390/life11090884
Chicago/Turabian Style
Nordeen, Steven K., Lih-Jen Su, Gregory A. Osborne, Perry M. Hayman, David J. Orlicky, Veronica M. Wessells, Adrie van Bokhoven, and Thomas W. Flaig.
2021. "Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer" Life 11, no. 9: 884.
https://doi.org/10.3390/life11090884
APA Style
Nordeen, S. K., Su, L.-J., Osborne, G. A., Hayman, P. M., Orlicky, D. J., Wessells, V. M., van Bokhoven, A., & Flaig, T. W.
(2021). Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. Life, 11(9), 884.
https://doi.org/10.3390/life11090884
